strengthens the commercial leadership structure and appoints Nikolaj Sørensen
as new CEO and Martin Nicklasson as Executive Chairman
Nikolaj Sørensen, currently Chief Commercial Officer of Orexo, will be promoted to CEO of the company and Martin Nicklasson, currently Chairman of the Board, will be appointed Executive Chairman, both effective as of today.
Nikolaj Sørensen will succeed Anders Lundström, who will step down as CEO of the company after successful two year tenure.
has been central to this process.
In order to enhance the company focus on this opportunity, the Board has decided that operations, which today primarily are directed towards support of Zubsolv, should be firmly anchored under Nikolaj Sørensen's
Nikolaj Sørensen commented "I am excited and honored to be appointed CEO of Orexo, and I look forward to closely working with Martin Nicklasson to secure the optimal commercialization for Zubsolv and Abstral in the United States."
I'm looking forward to working with Nikolaj Sørensen
and the leadership team towards this common goal."
Nikolaj Sørensen joined Orexo AB in October 2011 and has focused the company's activities towards the business opportunities within the US opioid addiction market.
, Chief Commercial Officer
Tel: +46-703-50 78 88, Email: firstname.lastname@example.org